Wick W - Search Results

1

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, Henriksson R, Le Rhun E, Balana C, Chinot O, Bendszus M, Reijneveld JC, Dhermain F, French P, Marosi C, Watts C, Oberg I, Pilkington G, Baumert BG, Taphoorn MJB, Hegi M, Westphal M, Reifenberger G, Soffietti R, Wick W; European Association for Neuro-Oncology (EANO) Task Force on Gliomas. Weller M, et al. Among authors: wick w. Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5. Lancet Oncol. 2017. PMID: 28483413 Free article. Review.

2

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

Fulda S, Wick W, Weller M, Debatin KM. Fulda S, et al. Among authors: wick w. Nat Med. 2002 Aug;8(8):808-15. doi: 10.1038/nm735. Epub 2002 Jul 15. Nat Med. 2002. PMID: 12118245

3

Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.

Wick W, Hermisson M, Kortmann RD, Küker WM, Duffner F, Dichgans J, Bamberg M, Weller M. Wick W, et al. J Neurooncol. 2002 Sep;59(2):151-5. doi: 10.1023/a:1019641314661. J Neurooncol. 2002. PMID: 12241108 Clinical Trial.

4

Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins.

Rieger J, Wick W, Weller M. Rieger J, et al. Among authors: wick w. Glia. 2003 Jun;42(4):379-89. doi: 10.1002/glia.10210. Glia. 2003. PMID: 12730958

5

P-glycoprotein and multidrug resistance-associated protein mediate specific patterns of multidrug resistance in malignant glioma cell lines, but not in primary glioma cells.

Bähr O, Rieger J, Duffner F, Meyermann R, Weller M, Wick W. Bähr O, et al. Among authors: wick w. Brain Pathol. 2003 Oct;13(4):482-94. doi: 10.1111/j.1750-3639.2003.tb00479.x. Brain Pathol. 2003. PMID: 14655754 Free PMC article.

6

Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.

Wick W, Wick A, Küker W, Dichgans J, Weller M. Wick W, et al. Among authors: wick a. J Neurooncol. 2004 Oct;70(1):73-5. doi: 10.1023/b:neon.0000040826.30636.4a. J Neurooncol. 2004. PMID: 15527110

7

BCL-2-induced glioma cell invasiveness depends on furin-like proteases.

Wick W, Wild-Bode C, Frank B, Weller M. Wick W, et al. J Neurochem. 2004 Dec;91(6):1275-83. doi: 10.1111/j.1471-4159.2004.02806.x. J Neurochem. 2004. PMID: 15584904 Free article.

8

How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.

Wick W, Weller M. Wick W, et al. J Clin Oncol. 2005 Jun 20;23(18):4235-6; author reply 4236. doi: 10.1200/JCO.2004.00.8417. J Clin Oncol. 2005. PMID: 15961774 No abstract available.

9

Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?

Wick W, Menn O, Meisner C, Steinbach J, Hermisson M, Tatagiba M, Weller M. Wick W, et al. Onkologie. 2005 Aug;28(8-9):391-6. doi: 10.1159/000086375. Epub 2005 Aug 29. Onkologie. 2005. PMID: 16160401

10

Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma.

Wick W, Naumann U, Weller M. Wick W, et al. Curr Pharm Des. 2006;12(3):341-9. doi: 10.2174/138161206775201901. Curr Pharm Des. 2006. PMID: 16454748 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

707 results

Search Page

Filters